# argenx to Host Myositis R&D Webinar on June 23, 2026
Canonical URL: https://biopharmsignal.com/news/ARGX/argenx-to-host-myositis-r-d-webinar-on-june-23-2026-5b497566
Ticker: ARGX
Company: Argenx
Source: Argenx
Published: 2026-05-28 05:00 EST
## Summary

May 28, 2026Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...

## Article Body
May 28, 2026

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight: Advancing FcRn Leadership into Autoimmune Myositis” on Tuesday, June 23, 2026, at 2:00pm ET.

The second webinar in the Company’s ‘mini’ series highlighting the argenx pipeline and research and development strategy will focus on myositis, an autoimmune rheumatic disease associated with progressive muscle damage and significant patient burden. The argenx team and leading clinicians treating myositis will discuss emerging insights into disease biology, including the role of autoantibodies as key disease drivers, as well as the ALKIVIA clinical program design and the clinical and commercial opportunity for efgartigimod.

A webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors . A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

About argenx argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn , Instagram , Facebook , and YouTube .

Contacts

Media:

Colin McBean cmcbean@argenx.com

Investors:

Alexandra Roy aroy@argenx.com
## Recent Company News
- 2026-07-27 05:00 EST — [argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class anti-CD122 Antibody, FB102, to its Immunology Pipeline](https://biopharmsignal.com/news/ARGX/argenx-to-acquire-forte-biosciences-inc-adding-first-in-class-anti-cd122-antibod-fae8b638) — Source: Argenx
- 2026-07-23 05:00 EST — [argenx Reports Half Year 2026 Financial Results and Provides Second Quarter Business Update](https://biopharmsignal.com/news/ARGX/argenx-reports-half-year-2026-financial-results-and-provides-second-quarter-busi-a7cfe76d) — Source: Argenx
- 2026-07-16 05:00 EST — [argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026](https://biopharmsignal.com/news/ARGX/argenx-to-report-half-year-2026-financial-results-and-second-quarter-business-up-391e9c59) — Source: Argenx
- 2026-06-23 05:00 EST — [argenx to Host Autoimmune Myositis R&D Webinar](https://biopharmsignal.com/news/ARGX/argenx-to-host-autoimmune-myositis-r-d-webinar-30608012) — Source: Argenx
- 2026-06-03 05:00 EST — [argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren’s Disease at EULAR 2026](https://biopharmsignal.com/news/ARGX/argenx-presents-new-efgartigimod-data-showing-long-term-sustained-patient-benefi-e5897167) — Source: Argenx
## Related News
- 2026-07-27 15:00 EST — CAPR — [Capricor Comments on Briefing Materials Ahead of July 29 FDA Advisory Committee Meeting for Deramiocel](https://biopharmsignal.com/news/CAPR/capricor-comments-on-briefing-materials-ahead-of-july-29-fda-advisory-committee--3a3054d7)
- 2026-07-27 13:00 EST — SPRO — [Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer](https://biopharmsignal.com/news/SPRO/spero-therapeutics-appoints-debra-jeske-zack-m-d-ph-d-as-chief-medical-officer-81a269de)
- 2026-07-27 12:32 EST — ICCM — [IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site](https://biopharmsignal.com/news/ICCM/icecure-medical-kicks-off-its-post-marketing-choice-study-for-the-low-risk-breas-9de814e1)
- 2026-07-27 12:10 EST — VERU — [Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss](https://biopharmsignal.com/news/VERU/veru-announces-full-enrollment-for-phase-2b-plateau-clinical-trial-of-enobosarm--ce89119d)
- 2026-07-27 12:08 EST — BIAF — [bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung](https://biopharmsignal.com/news/BIAF/bioaffinity-technologies-publishes-new-clinical-framework-addressing-growing-mar-0496e8ef)